HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by De Jonge, J. Articles by Thielemans, K. Search for Related Content PubMed PubMed Citation Articles by De Jonge, J. Articles by Thielemans, K.

In Vivo Retargeting of T Cell Effector Function by Recombinant Bispecific Single Chain Fv (Anti-CD3 x Anti-Idiotype) Induces Long-Term Survival in the Murine BCL1 Lymphoma Model¹

Jan De Jonge^*, Carlo Heirman^*, Marijke de Veerman^*, Sonja Van Meirvenne^*, Muriel Moser, Oberdan Leo and Kris Thielemans^2,*

^* Vrije Universiteit Brussel, Medical School, Laboratory of Physiology-Immunology, Brussels, Belgium; and Université Libre de Bruxelles, Laboratoire de Physiologie Animale, St-Genesius-Rode, Belgium

As demonstrated in several preclinical models, bispecific Abs are attractive immunotherapeutic agents for tumor treatment. We have previously reported that a bacterially produced anti-CD3 x antitumor bispecific single chain variable fragment of Ab fragment (BsscFv), which is capable of retargeting CTLs toward BCL1 tumor cells, exhibits antitumor activity in vitro. To further facilitate BsscFv production, the coding sequence was subcloned in a eukaryotic expression vector and introduced into Chinese hamster ovary cells for large-scale production. In this report, we have determined the serum stability and the clearance rate from the circulation of BsscFv. Most important, we prove here the therapeutic value of BsscFv in the treatment of BCL1 lymphoma, a murine model for human non-Hodgkin’s lymphoma. Tumor-bearing mice that were treated with rscFv in combination with staphylococcal enterotoxin B superantigen, human rIL-2, or murine rIL-12 showed long-term survival, whereas untreated mice all died. This is the first report of the successful in vivo use of BsscFv as an immunotherapeutic agent. Furthermore, long-term survival was the result of complete tumor removal and was not due to the induction of dormancy.

This article has been cited by other articles:

				P. Ruf and H. Lindhofer Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody Blood, October 15, 2001; 98(8): 2526 - 2534. [Abstract] [Full Text] [PDF]

				R. Schoonjans, A. Willems, S. Schoonooghe, W. Fiers, J. Grooten, and N. Mertens Fab Chains As an Efficient Heterodimerization Scaffold for the Production of Recombinant Bispecific and Trispecific Antibody Derivatives J. Immunol., December 15, 2000; 165(12): 7050 - 7057. [Abstract] [Full Text] [PDF]

				B. Cochlovius, S. M. Kipriyanov, M. J. J. G. Stassar, O. Christ, J. Schuhmacher, G. Strau{beta}, G. Moldenhauer, and M. Little Treatment of Human B Cell Lymphoma Xenografts with a CD3 CD19 Diabody and T Cells J. Immunol., July 15, 2000; 165(2): 888 - 895. [Abstract] [Full Text] [PDF]

				K. Els Conrath, M. Lauwereys, L. Wyns, and S. Muyldermans Camel Single-domain Antibodies as Modular Building Units in Bispecific and Bivalent Antibody Constructs J. Biol. Chem., March 2, 2001; 276(10): 7346 - 7350. [Abstract] [Full Text] [PDF]